TIGIT Target - Development.

The research on the biological mechanism of L cell room and the exploration of combined drug therapy based on animal experiments provide sufficient support for the combination of tigit targeted antibody and PD1 / PD-L1 targeted antibody.overall R & D situation according to the statistics in the small section, up to now, no tigit targeted antibody drugs have been approved, and there are 10 tigit targeted antibody drugs that are active in clinical stage: tiragolumab of Roche is in the lead and has entered phase III clinical; mk-7684 of MSD, ab154 of arcus and bms-986207 of BMS are in phase II, and other projects are in phase I.this target is still emerging.from the overall clinical development strategy, it is very clear that it is combined with PD1 / PD-L1 targeted antibody.at present, Roche's tiragolumab has two phase III clinical trials, both of which are combined with its own PD-L1 targeted antibody atezolizumab (PD-L1 targeted monoclonal antibody); moshadong has opened four clinical trials for mk-7684, which are combined with pembrolizumab (PD-1 targeted monoclonal antibody); arcus has developed ab154 with his own zimberelimab (PD-1 targeted monoclonal antibody) ）In addition, BMS also combined bms-986207 with nivolumab (PD-1 targeted monoclonal antibody).even for tigit targeted antibodies in the first stage of clinical stage, the combination strategy has also begun: Xinda bio used ibi939 with its own sintilimab (PD-1 targeted monoclonal antibody), Baiji Shenzhou combined bgb-a1217 with tisliezumab (PD-1 targeted monoclonal antibody), etc.R & D strategy and logic Roche is currently conducting two phase III clinical trials for tiragolumab: skyscraper-01 and skyscraper-02.atezolizumab was approved by FDA in March last year to treat previously untreated extensive small cell lung cancer with chemotherapy.and a phase III clinical trial of tiragolumab, skyscraper-02 (nct04256421), aims to detect whether the increase of tiragolumab has an effect on the treatment of extensive stage small cell lung cancer (first-line) on the basis of atezolizumab combined with chemotherapy.another phase III clinical trial of tiragolumab, skyscraper-01 (nct04294810), aims to compare the efficacy of "tiragolumab + atezolizumab" and atezolizumab monotherapy in the treatment of non-small cell lung cancer (first-line) with high expression of PD-L1.however, in the last May, the FDA approved atezolizumab monotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with high expression of PD-L1 and without EGFR or ALK gene mutation.it can be seen that the purpose of clinical trials has been carried out to test whether tiragolumab can further improve the approved therapy.there is a clinical trial of mk-7684 in MSD, which has entered phase II, and the rest is in phase I / II: the design idea of the trial is the same.the above indications have also been approved for pembrolizumab treatment (monotherapy or combination) or further expansion based on the existing approved indications.therefore, as can be seen from the leading projects, the layout logic of clinical trials is to challenge the existing therapies around PD-1 / PD-L1 mAb, or optimize or replace them.especially when PD-1 / PD-L1 monoclonal antibody and its indications are developed by ourselves, this strategy reflects the continuity and improvement of the sponsors in product development.for other projects in the early stage, they can also adopt the same strategy. They can challenge their own PD-1 / PD-L1 mAbs or others' PD-1 / PD-L1 mAbs. this strategy is not only a direct template for these subsequent tigit antibodies, but also an idea that can be extended to other indications, that is, to replace "PD-1 / PD-L1" with "tigit + PD-1 / PD-L1". the PD-1 monoclonal antibodies of Xinda biology and Baiji Shenzhou have been approved, and many major indications that have not yet been approved are also advancing rapidly. I believe that they will carry out a series of combined trials in the future. Although Hengrui's tigit antibody is still in the preclinical stage, it is only a matter of time before it enters the war situation. The pioneers in front will open up a broad road for it. summary with the development of tumor immunotherapy and the deepening of the concept of combined drug use, the logic of antibody drug development is not only the full demonstration of single target, but also more and more towards the direction of multi-target collaborative layout. please contact wechat: wz910605 business cooperation contact: welcome to forward and share. If any other media or website needs to reprint or quote all the copyright content of this website, it must be authorized and marked "transferred from: biopharmaceutical monograph" in an eye-catching position.